News Related to DMPK mRNA Levels

Related coverage linked through entity extraction aliases.

FDA Pauses U.S. Enrollment in Myotonic Dystrophy Trial After Serious Adverse Event

Mar 06, 2026

The FDA has placed a partial hold on U.S. enrollment in a Phase 2 trial of del-desiran for myotonic dystrophy type 1, citing preclinical mouse data showing blood pressure drops not seen in humans, following a serious adverse event in earlier testing.

Del-desiran Shows Muscle Delivery and Splicing Improvements in Phase 1/2 DM1 Trial

Feb 19, 2026

Phase 1/2 MARINA trial results published in NEJM show del-desiran achieved approximately 40% reduction in toxic DMPK mRNA in muscle tissue and improvements in myotonia and functional measures in myotonic dystrophy type 1 patients, with acceptable safety profile.